Clinical trial
Intranasal Fentanyl for the Treatment of Breakthrough Pain in Cancer Patients…
NCT00345735 · Nycomed, Industry · Completed
Key facts
| NCT number | NCT00345735 |
|---|---|
| Title | Intranasal Fentanyl for the Treatment of Breakthrough Pain in Cancer Patients (FT-017-IM) |
| Official title | Intranasal Fentanyl for the Treatment of Breakthrough Pain in Cancer Patients. A Randomised, Double-blind, Placebo-controlled, Cross-over Confirmatory Trial Testing Fentanyl and Placebo in Eight Breakthrough Pain Episodes |
| Lead sponsor | Nycomed, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cancer, Pain |
| Intervention type | Drug |
| Interventions | Fentanyl |
| Enrollment | 150 |
| Start date | May 1, 2006 |
| Primary completion | Oct 1, 2007 |
| Completion | Oct 1, 2007 |
| First posted | Jun 28, 2006 |
| Last update posted | May 7, 2012 |
| Countries | Denmark |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: